In the absence of head-to-head studies, oncologists are looking across pivotal trials and are encouraged by Itovebi's safety and efficacy versus Piqray.

Expert Rev Clin Pharmacol. 2012;5(3):319-336. Finally, a recent study suggested that although prasugrel significantly reduces thrombotic events in patients with ACS undergoing PCI because of its ...

Targeting the ER and PI3K pathway: Novel drugs and combinations Date/Time: Wednesday, December 11, 8:00-9:30 a.m. ET (7:00-8:30 a.m. CT) Data support planned initiation of Phase 3 pivotal trial ...

Zhejiang Province Key Laboratory of Smart Management & Application of Modern Agricultural Re-sources, School of Information Engineering, Huzhou University, Huzhou 313000, Zhejiang Province,China ...